Tech Company Financing Transactions
Trevena Funding Round
Forest Laboratories invested in a $30 million venture round for Trevena. The round was announced on 5/10/2013.
Transaction Overview
Company Name
Announced On
5/10/2013
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Undisclosed
Investors
Forest Laboratories (David Solomon)
Proceeds Purpose
The agreement includes a $30 million equity investment by Forest in Trevena and the grant by Trevena to Forest of an option to exclusively license TRV027 on a worldwide basis following completion of the planned Phase 2b clinical trial which will be funded by Trevena.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1018 West 8th Ave. A
King of Prussia, PA 19406
USA
King of Prussia, PA 19406
USA
Phone
Website
Email Address
Overview
Trevena (NASDAQ: TRVN) is a drug discovery company focused on developing pharmaceutical products targeting G-protein coupled receptors (GPCRs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Maxine Gowen
Chief Financial Officer
Roberto Cuca
Chief Scientific Officer
Michael Lark
VP - Bus. Development
David Soergel
VP - General Counsel
John Limongelli
Browse more venture capital transactions:
Prev: 5/10/2013: Crystalplex venture capital transaction
Next: 5/10/2013: CapLinked venture capital transaction
Share this article
About Database of VC Transactions
We document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs